Total Payments
$226,111
2023 Payments
$271.35
Companies
16
Transactions
138
Medicare Patients
453
Medicare Billing
$56,371
Payment Breakdown by Category
Consulting$138,569 (61.3%)
Travel$44,372 (19.6%)
Research$38,236 (16.9%)
Food & Beverage$3,658 (1.6%)
Other$1,263 (0.6%)
Education$13.89 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $138,569 | 20 | 61.3% |
| Travel and Lodging | $44,372 | 32 | 19.6% |
| Unspecified | $38,236 | 11 | 16.9% |
| Food and Beverage | $3,658 | 73 | 1.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,263 | 1 | 0.6% |
| Education | $13.89 | 1 | 0.0% |
Payments by Type
General
$187,875
127 transactions
Research
$38,236
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $73,750 | 17 | $0 (2022) |
| Eli Lilly and Company | $58,835 | 40 | $0 (2021) |
| UCB SA | $23,818 | 13 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $22,071 | 20 | $0 (2021) |
| Novartis Pharma AG | $16,681 | 6 | $0 (2019) |
| PFIZER INC. | $12,253 | 8 | $0 (2022) |
| UCB, Inc. | $10,363 | 7 | $0 (2022) |
| Lilly USA, LLC | $7,033 | 4 | $0 (2023) |
| ABBVIE INC. | $576.47 | 8 | $0 (2022) |
| Janssen Biotech, Inc. | $328.12 | 6 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $271.35 | 3 | Janssen Biotech, Inc. ($250.00) |
| 2022 | $4,760 | 6 | UCB, Inc. ($4,600) |
| 2021 | $7,270 | 7 | Eli Lilly and Company ($4,200) |
| 2020 | $10,114 | 4 | Novartis Pharmaceuticals Corporation ($10,101) |
| 2019 | $55,349 | 32 | Janssen Scientific Affairs, LLC ($32,515) |
| 2018 | $109,386 | 49 | Eli Lilly and Company ($39,990) |
| 2017 | $38,961 | 37 | UCB SA ($18,493) |
All Payment Transactions
138 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/12/2023 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $21.35 | General |
| 11/11/2023 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI ARIA | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Immunology | ||||||
| 11/11/2023 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI ARIA | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Immunology | ||||||
| 11/14/2022 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $90.78 | General |
| Category: Immunology | ||||||
| 11/14/2022 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.25 | General |
| Category: Immunology | ||||||
| 04/26/2022 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $12.77 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 03/11/2022 | UCB, Inc. | — | — | Cash or cash equivalent | $4,600.00 | Research |
| Study: A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEK | ||||||
| 02/18/2022 | Amgen Inc. | — | Education | In-kind items and services | $13.89 | General |
| 01/11/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $22.89 | General |
| Category: IMMUNOLOGY | ||||||
| 12/01/2021 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $39.86 | General |
| Category: Immunology | ||||||
| 10/06/2021 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $4,200.00 | General |
| 09/28/2021 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $17.11 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 07/28/2021 | Lilly USA, LLC | — | Consulting Fee | Cash or cash equivalent | $2,450.00 | General |
| 06/01/2021 | UCB, Inc. | — | — | Cash or cash equivalent | $420.00 | Research |
| Study: A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND EFFICACY OF BIMEKIZUMAB IN SUBJECTS WITH ANKYLOSING SPONDYLITIS | ||||||
| 04/20/2021 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $25.36 | General |
| Category: Inflammation | ||||||
| 04/05/2021 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $117.56 | General |
| Category: IMMUNOLOGY | ||||||
| 10/26/2020 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $88.01 | General |
| Category: IMMUNOLOGY | ||||||
| 09/24/2020 | Novartis Pharmaceuticals Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,263.00 | General |
| 06/03/2020 | Novartis Pharmaceuticals Corporation | — | — | In-kind items and services | $8,750.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT | ||||||
| 01/17/2020 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), STELARA | Food and Beverage | In-kind items and services | $12.86 | General |
| Category: Immunology | ||||||
| 11/12/2019 | Janssen Scientific Affairs, LLC | SIMPONI ARIA (Biological) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: Immunology | ||||||
| 11/11/2019 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $107.53 | General |
| Category: Immunology | ||||||
| 11/07/2019 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $4,800.00 | General |
| 11/01/2019 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $12.42 | General |
| Category: Immunology | ||||||
| 10/08/2019 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $3.76 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED 16 WEEK STUDY FOLLOWED BY LONG TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB LY2439821 IN TNFI EXPERIENCED PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | Eli Lilly and Company | $10,178 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $8,750 | 1 |
| A MULTICENTER LONG-TERM EXTENSION STUDY OF 104 WEEKS INCLUDING A DOUBLE BLIND PLACEBO CONTROLLED 40 WEEK RANDOMIZED WITHDRAWAL RETREATMENT PERIOD TO EVALUATE THE MAINTENANCE OF TREATMENT EFFECT OF IXEKIZUMAB LY2439821 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS | Eli Lilly and Company | $7,195 | 4 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO-CONTROLLED 16-WEEK STUDY FOLLOWED BY LONG-TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB -LY2439821- IN BDMARD-NAIVE PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | Eli Lilly and Company | $7,093 | 2 |
| A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEK | UCB, Inc. | $4,600 | 1 |
| A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND EFFICACY OF BIMEKIZUMAB IN SUBJECTS WITH ANKYLOSING SPONDYLITIS | UCB, Inc. | $420.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 102 | 209 | $58,186 | $14,106 |
| 2022 | 3 | 116 | 230 | $64,864 | $15,891 |
| 2021 | 4 | 120 | 212 | $57,763 | $14,423 |
| 2020 | 4 | 115 | 211 | $42,052 | $11,952 |
Total Patients
453
Total Services
862
Medicare Billing
$56,371
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 65 | 130 | $41,210 | $11,623 | 28.2% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 23 | 44 | $16,276 | $2,265 | 13.9% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 14 | 35 | $700.00 | $217.61 | 31.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 75 | 156 | $49,452 | $13,781 | 27.9% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 24 | 40 | $14,868 | $1,944 | 13.1% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2022 | 17 | 34 | $544.00 | $165.04 | 30.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 63 | 126 | $39,942 | $11,573 | 29.0% |
| 20610 | Aspiration and/or injection of large joint or joint capsule | Office | 2021 | 23 | 33 | $12,833 | $1,680 | 13.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 19 | 20 | $4,460 | $1,020 | 22.9% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2021 | 15 | 33 | $528.00 | $150.11 | 28.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 68 | 120 | $27,600 | $9,386 | 34.0% |
| 20610 | Aspiration and/or injection of large joint or joint capsule | Office | 2020 | 13 | 25 | $10,642 | $1,254 | 11.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 17 | 20 | $3,074 | $1,095 | 35.6% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2020 | 17 | 46 | $736.00 | $216.33 | 29.4% |
About Dr. John Reveille, M.D
Dr. John Reveille, M.D is a Internal Medicine healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1295753408.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Reveille, M.D has received a total of $226,111 in payments from pharmaceutical and medical device companies, with $271.35 received in 2023. These payments were reported across 138 transactions from 16 companies. The most common payment nature is "Consulting Fee" ($138,569).
As a Medicare-enrolled provider, Reveille has provided services to 453 Medicare beneficiaries, totaling 862 services with total Medicare billing of $56,371. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Rheumatology
- Location Houston, TX
- Active Since 07/17/2006
- Last Updated 02/11/2008
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1295753408
Products in Payments
- SIMPONI ARIA (Biological) $73,675
- TALTZ (Drug) $58,072
- COSENTYX (Biological) $23,380
- ENBREL (Biological) $12,228
- Cimzia (Drug) $5,419
- COSENTYX_COSENTYX_DERMATOLOGY (Biological) $5,258
- Humira (Biological) $553.58
- TREMFYA (Drug) $399.89
- Enbrel (Biological) $295.22
- ORENITRAM (Drug) $32.60
- XELJANZ (Drug) $25.66
- RINVOQ (Biological) $22.89
- BENLYSTA (Biological) $18.06
- SAPHNELO (Biological) $17.11
- ILARIS (Biological) $15.00
- ORENCIA (Biological) $12.42
- Rituxan (Biological) $12.00
- SIMPONI (Biological) $3.47
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Houston
Stephen Pappas, M.d, M.D
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
Mohamed Othman, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M
Dr. Aung Naing, Md, MD
Internal Medicine — Payments: $925,146
Internal Medicine $925,146
Miguel Escobar, M.d, M.D
Internal Medicine — Payments: $924,228
Internal Medicine $924,228
Dr. Christie Ballantyne, Md, MD
Internal Medicine — Payments: $815,154
Internal Medicine $815,154
John Heymach, M.d, M.D
Internal Medicine — Payments: $786,947
Internal Medicine $786,947